WO2003042188A1 - Triazole derivative and medicinal composition containing the same - Google Patents

Triazole derivative and medicinal composition containing the same Download PDF

Info

Publication number
WO2003042188A1
WO2003042188A1 PCT/JP2002/011960 JP0211960W WO03042188A1 WO 2003042188 A1 WO2003042188 A1 WO 2003042188A1 JP 0211960 W JP0211960 W JP 0211960W WO 03042188 A1 WO03042188 A1 WO 03042188A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
same
composition containing
medicinal composition
triazole derivative
Prior art date
Application number
PCT/JP2002/011960
Other languages
French (fr)
Japanese (ja)
Inventor
Fumihito Setsu
Eijirou Umemura
Kazue Sasaki
Kaori Tadauchi
Takafumi Okutomi
Keiko Ohtsuka
Shou Takahata
Original Assignee
Meiji Seika Kaisha, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha, Ltd. filed Critical Meiji Seika Kaisha, Ltd.
Publication of WO2003042188A1 publication Critical patent/WO2003042188A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Abstract

A compound usable in treatments for fungal infectious diseases. It is a compound represented by the following formula (I) or a pharmacologically acceptable salt or solvate thereof: (I) wherein A represents substituted phenyl or a 5- to 7-membered, (un)saturated, optionally substituted heterocyclic group, provided that the substituted phenyl may have been substituted by substituted C1-6 alkyl, optionally substituted sulfonyl, a 5- to 7-membered, (un)saturated, carbocyclic or heterocyclic group, etc.; and p is 0 or 1.
PCT/JP2002/011960 2001-11-15 2002-11-15 Triazole derivative and medicinal composition containing the same WO2003042188A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001349783A JP2005298333A (en) 2001-11-15 2001-11-15 Novel triazole derivative and antimycotic agent having the same as active ingredient
JP2001-349783 2001-11-15

Publications (1)

Publication Number Publication Date
WO2003042188A1 true WO2003042188A1 (en) 2003-05-22

Family

ID=19162401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/011960 WO2003042188A1 (en) 2001-11-15 2002-11-15 Triazole derivative and medicinal composition containing the same

Country Status (2)

Country Link
JP (1) JP2005298333A (en)
WO (1) WO2003042188A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345178B2 (en) 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7829556B2 (en) 2007-06-20 2010-11-09 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8399476B2 (en) 2007-02-28 2013-03-19 Sanofi Imidazo[1,2-a]pyridines and their use as pharmaceuticals

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0115400A1 (en) * 1983-01-21 1984-08-08 Pfizer Limited Triazole antifungal agents
US4503063A (en) * 1983-05-07 1985-03-05 Pfizer Inc. N-Acyl 3-aryl-3-hydroxy-4-(1H-1,2,4-triazol-1-yl)-butyramide antifungal agents
WO1992017474A1 (en) * 1991-04-04 1992-10-15 Pfizer Limited Triazole antifungal agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0115400A1 (en) * 1983-01-21 1984-08-08 Pfizer Limited Triazole antifungal agents
US4503063A (en) * 1983-05-07 1985-03-05 Pfizer Inc. N-Acyl 3-aryl-3-hydroxy-4-(1H-1,2,4-triazol-1-yl)-butyramide antifungal agents
WO1992017474A1 (en) * 1991-04-04 1992-10-15 Pfizer Limited Triazole antifungal agents

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345178B2 (en) 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8044198B2 (en) 2005-08-04 2011-10-25 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8163908B2 (en) 2005-08-04 2012-04-24 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8399476B2 (en) 2007-02-28 2013-03-19 Sanofi Imidazo[1,2-a]pyridines and their use as pharmaceuticals
US7829556B2 (en) 2007-06-20 2010-11-09 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8247565B2 (en) 2007-06-20 2012-08-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds

Also Published As

Publication number Publication date
JP2005298333A (en) 2005-10-27

Similar Documents

Publication Publication Date Title
EP1674452A4 (en) Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor
EP1548008A4 (en) Compound having tgf-beta inhibitory activity and medicinal composition containing the same
NO950297L (en) Prolinamidderivater
RS51444B (en) Lactam-containing compounds and derivatives thereof as factor xa inhibitors
RS50140B (en) Percyquinnin, a process for its production, and its use as a pharmaceutical
WO2003082205A3 (en) Compounds and methods
WO2001072728A3 (en) Novel piperazine derivatives
AU5577598A (en) Pyrrolidine derivatives having phospholipase a2 inhibitory activity
AU6703300A (en) Fungicides
RS51146B (en) Novel diphenyl azetidinone with improved phzsiological characteristics, corresponding production method, medicaments containing said compound and use of the latter
NO20040881L (en) Oral antidiabetic agents.
WO2002076918A8 (en) NF-λB INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT
WO2004014868A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
WO2003053971A8 (en) Pyridoquinoxaline antivirals
WO2003082192A3 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
WO2003047505A3 (en) Topoisomerase poison agents
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
DE60114640D1 (en) Antithrombosemittel
WO2003054001A3 (en) Method for preparing echinocandin derivatives and their compositions
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
WO2003031414A1 (en) Novel heterocyclic compound and anti-inflammatory agent
WO2003097585A3 (en) Amidoacetonitrile compounds
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
WO2003042188A1 (en) Triazole derivative and medicinal composition containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP